Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BEhavioural Weight Management: COMponents of Effectiveness (BE:COME) Synopsis.

Health technology assessment (Winchester, England)·2026
Same author

Mapping components of behavioural weight management interventions using electronic survey and component selection by expert consensus: the BE:COME Study.

Health technology assessment (Winchester, England)·2026
Same author

A deep ensemble encoder network method for improved polygenic risk score prediction.

BioData mining·2026
Same author

A digital diagnostic pathway for heart failure: an economic evaluation.

Cost effectiveness and resource allocation : C/E·2026
Same author

Unloading the excess baggage: key informant interviews with Malaysian stakeholders on healthcare disinvestment initiatives.

International journal of technology assessment in health care·2026
Same author

Risk assessment tools for predicting transfusion in surgery: a systematic review and meta-analysis.

Health technology assessment (Winchester, England)·2025
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: May 31, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Systemic lupus erythematosus.

Rajan Madhok1, Olivia Wu

  • 1Glasgow Royal Infirmary, Glasgow, UK.

BMJ Clinical Evidence
|June 24, 2011
PubMed
Summary
This summary is machine-generated.

This systematic review evaluates treatments for systemic lupus erythematosus (SLE), focusing on joint, skin, kidney, and neuropsychiatric symptoms. It summarizes evidence on interventions like corticosteroids, hydroxychloroquine, and methotrexate for SLE management.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Related Experiment Videos

Last Updated: May 31, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Area of Science:

  • Rheumatology
  • Systemic Autoimmune Diseases

Background:

  • Systemic lupus erythematosus (SLE) disproportionately affects young women and children globally, with varying prevalence rates across different populations.
  • Understanding the epidemiology of SLE is crucial for targeted public health initiatives and resource allocation.

Purpose of the Study:

  • To systematically review the effects of various treatments on joint, skin, kidney (proliferative lupus nephritis), and neuropsychiatric manifestations of SLE.
  • To assess the safety and effectiveness of interventions for non-organ-threatening and organ-specific symptoms in SLE patients.

Main Methods:

  • Conducted a systematic literature search up to December 2007 across major databases (Medline, Embase, Cochrane Library).
  • Included data from 11 systematic reviews and randomized controlled trials (RCTs).
  • Incorporated safety alerts from regulatory agencies (FDA, MHRA).

Main Results:

  • Identified and evaluated evidence for multiple interventions, including acitretin, corticosteroids, hydroxychloroquine, methotrexate, and NSAIDs.
  • Performed a GRADE assessment to determine the quality of evidence for each intervention.
  • The review synthesized findings on treatments for diverse SLE manifestations.

Conclusions:

  • Presents a comprehensive overview of the effectiveness and safety of key interventions for SLE.
  • Provides evidence-based information on treatments for joint, cutaneous, renal, and neuropsychiatric lupus.
  • Highlights the importance of a multi-faceted approach to managing SLE symptoms.